Stocks · News reference
Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XProInitial engagement marks QCi's
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
INmune Bio (NASDAQ:INMB) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Filed: 2026-09-14 AccNo: 0001213900-26-099700 Size: 262 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may
Filed: 2026-10-02 AccNo: 0001213900-26-106409 Size: 11 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Quantum Computing Inc. (QUBT) is transitioning from a pre-commercial quantum computing company to one generating real revenue through photonics and semiconductor manufacturing. Q2 2026 revenue reached $5.6 million (up from $61k YoY), but the company posted an $11.8 million net loss. While the company is developing promising products like NeuraWave (edge AI) and quantum security systems, it faces significant execution risks, heavy capital spending, competitive pressures, and remains unprofitable. Analysts suggest it may be suitable only for risk-tolerant investors as a small portfolio position.